300
Participants
Start Date
November 7, 2023
Primary Completion Date
December 31, 2028
Study Completion Date
January 31, 2029
Gemcitabine
◦ Gemcitabine 800 mg/mq iv, day 1 and 8 of 21-day cycles, for 3 cycles
Nab paclitaxel
◦ Nab-paclitaxel 100 mg/mq, day 1 and 8 of 21-day cycles, for 3 cycles
Cisplatin
◦ Cisplatin 25 mg/mq iv, day 1 and 8 of 21-day cycles, for 3 cycles
Curative Surgery
Curative surgery on primary tumor
Capecitabine
1250 mg/m2 given orally twice daily on days 1 to 14 of a 3 weekly cycle for a total of 8 cycles
RECRUITING
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan
NOT_YET_RECRUITING
Ospedali Riuniti di Ancona, Ancona
NOT_YET_RECRUITING
ASST Papa Giovanni XXIII, Bergamo
NOT_YET_RECRUITING
Oncologia Medica Policlinico Sant'Orsola - Malpighi, Bologna
NOT_YET_RECRUITING
ASST Spedali Civili, Brescia
NOT_YET_RECRUITING
Azienda Ospedaliera S. Croce e Carle, Cuneo
NOT_YET_RECRUITING
IRST Dino Amadori, Meldola
NOT_YET_RECRUITING
Humanitas Cancer Center, Milan
NOT_YET_RECRUITING
Ospedale Niguarda Cancer Center, Milan
NOT_YET_RECRUITING
Ospedale San Raffaele, Milan
NOT_YET_RECRUITING
Università di Modena, Modena
NOT_YET_RECRUITING
Ospedale S. Gerardo, Monza
NOT_YET_RECRUITING
IOV, Padua
NOT_YET_RECRUITING
Policlinico San Matteo, Pavia
RECRUITING
Azienda Ospedaliera Universitaria Pisa, Pisa
NOT_YET_RECRUITING
IRST (Cesena-Forlì-Meldola), Ravenna
NOT_YET_RECRUITING
Policlinico Gemelli, Rome
NOT_YET_RECRUITING
Azienda Ospedaliera Ordine Mauriziano, Turin
NOT_YET_RECRUITING
"AOUI Verona - Policlinico G.B. Rossi", Verona
Gruppo Oncologico del Nord-Ovest
OTHER